A new noradrenergic strategy to treat Impulsivity in Progressive Supranuclear Palsy
Lead Research Organisation:
University of Cambridge
Department Name: Clinical Neurosciences
Abstract
Progressive Supranuclear Palsy (PSP) is as complex as it is devastating for patients and families, combining a kind of movement disorder that does not respond to standard therapies, choking, loss of speech, personality changes, and dementia. Research by our team has shown that in the UK around 7,000 people are living with PSP.
Although physically very disabling, it is cognitive and personality changes in PSP that have the greatest impact on quality of life. Despite being slow and unresponsive for many activities, the same patients are often reckless and impulsive for actions that they do make. For example, a person living with PSP may "rush into things" and or "jump to conclusions" without thought for the consequences, or behave in a way that has high risks of falls or choking. These problems are also called "impulsivity". Impulsivity is highly dangerous for patients with PSP, in several different ways. It can make patients walking or moving around alone even though they have a very poor balance and fall. Eating too fast while choking is another form of impulsive behaviour which can lead to life-threatening chest infections. Impulsivity can also be highly distressing for carers and families.
There is currently no cure for PSP, although some of the symptoms, including impulsivity, are potentially treatable. However, there is yet a big gap between our knowledge of what is happening in brain cells of patients with PSP and how we should use the available treatments to help people with PSP to achieve the best possible quality of life. We must therefore build better "bridges" between basic studies and clinical trials.
To do this, our team will run a series of studies using the most advanced technologies in basic and clinical neuroscience, using advances in imaging, pharmacology, and psychology.
We will take advantage of the link between a brain chemical, noradrenaline, and the control of behavior. Noradrenaline is made by a tiny region of the brain called the locus coeruleus. It acts on other parts of the brain, especially the frontal lobe, to help control behavior, including flexible thinking and action control.
First, we will quantify the changes in the locus coeruleus, in PSP patients who we have followed through their illness in clinic and who then donated their brain to the Cambridge Brain Bank.
Second, we will measure the locus coeruleus in living patients with PSP. The locus coeruleus is small, and hard to see with normal brain scans. Working with Prof Emrah Duzel from Magdeburg, we will use the new technology of ultra-high field magnetic resonance imaging (known as "7 Tesla") to measure the size and degeneration of the locus coeruleus. His groups have developed new robust tools to measure this brain region. We will then use functional magnetic resonance imaging to measure how well the locus coeruleus connects to the frontal lobe and other brain regions.
Finally, we will measure the effects of a specific drug that enhances noradrenaline (called "atomoxetine") on impulsvity and cognition in PSP. This drug has been shown by our group and collaborators to improve impulsivity in a significant proportion of patients with Parkinson's disease, and in animal models of impulsivity. It is well tolerated, and approved for such research use in PSP. We believe that the results of our study will lead on to clinical trials for impulsivity in PSP and will eventually contribute to enhance the quality of life of people suffering from PSP.
Although physically very disabling, it is cognitive and personality changes in PSP that have the greatest impact on quality of life. Despite being slow and unresponsive for many activities, the same patients are often reckless and impulsive for actions that they do make. For example, a person living with PSP may "rush into things" and or "jump to conclusions" without thought for the consequences, or behave in a way that has high risks of falls or choking. These problems are also called "impulsivity". Impulsivity is highly dangerous for patients with PSP, in several different ways. It can make patients walking or moving around alone even though they have a very poor balance and fall. Eating too fast while choking is another form of impulsive behaviour which can lead to life-threatening chest infections. Impulsivity can also be highly distressing for carers and families.
There is currently no cure for PSP, although some of the symptoms, including impulsivity, are potentially treatable. However, there is yet a big gap between our knowledge of what is happening in brain cells of patients with PSP and how we should use the available treatments to help people with PSP to achieve the best possible quality of life. We must therefore build better "bridges" between basic studies and clinical trials.
To do this, our team will run a series of studies using the most advanced technologies in basic and clinical neuroscience, using advances in imaging, pharmacology, and psychology.
We will take advantage of the link between a brain chemical, noradrenaline, and the control of behavior. Noradrenaline is made by a tiny region of the brain called the locus coeruleus. It acts on other parts of the brain, especially the frontal lobe, to help control behavior, including flexible thinking and action control.
First, we will quantify the changes in the locus coeruleus, in PSP patients who we have followed through their illness in clinic and who then donated their brain to the Cambridge Brain Bank.
Second, we will measure the locus coeruleus in living patients with PSP. The locus coeruleus is small, and hard to see with normal brain scans. Working with Prof Emrah Duzel from Magdeburg, we will use the new technology of ultra-high field magnetic resonance imaging (known as "7 Tesla") to measure the size and degeneration of the locus coeruleus. His groups have developed new robust tools to measure this brain region. We will then use functional magnetic resonance imaging to measure how well the locus coeruleus connects to the frontal lobe and other brain regions.
Finally, we will measure the effects of a specific drug that enhances noradrenaline (called "atomoxetine") on impulsvity and cognition in PSP. This drug has been shown by our group and collaborators to improve impulsivity in a significant proportion of patients with Parkinson's disease, and in animal models of impulsivity. It is well tolerated, and approved for such research use in PSP. We believe that the results of our study will lead on to clinical trials for impulsivity in PSP and will eventually contribute to enhance the quality of life of people suffering from PSP.
Technical Summary
Impulsivity is a distressing and injurious aspect of PSP that is commonly under-recognised and poorly managed, even when coupled with balance and swallowing difficulty, with high risk of falls, injury, and choking. It typically coexists with apathy and bradykinesia, and is not relieved by current dopaminergic therapies. Impulsivity is a complex construct, with dissociable pharmacological and anatomical mechanisms that impair response inhibition, reward sensitivity, and decision making. Our group and collaborators have provided robust evidence that response inhibition in patients with Parkinsonian disorders linked to PSP (e.g., Parkinson's disease and frontotemporal dementia) is modulated by noradrenaline (NA), a key neurotransmitter mainly synthesized by the locus coeruleus (LC). Our overarching hypothesis is that enhancing NA function via NA reuptake inhibitors can improve response inhibition and impulsivity in PSP patients, mediated by the prefrontal cortex and its connections to the caudate and subthalamic nucleus.
This study will: (1) provide new quantitative evidence for the degree of loss of neurons in the LC, using post-mortem samples from PSP patients whom we have followed over the last 10 years; (2) apply advances in ultra-high-field MRI to quantify the LC in living PSP patients, together with a battery of behavioural tests of impulsivity and neuropsychology; (3) use formal models of behavior to track decision variables behind impulsive actions, and relate these to neural and disease markers, including brain network connectivity, and (4) test a repurposed drug, atomoxetine, to restore core neurocognitive systems governing the inhibition of motor responses in PSP.
Our work will promote bidirectional translational research, between non-clinical and clinical neuroscience, mapping disease states to preclinical models of cognition and behavior; and guide subsequent clinical trials with better outcome measures and patient selection and stratification.
This study will: (1) provide new quantitative evidence for the degree of loss of neurons in the LC, using post-mortem samples from PSP patients whom we have followed over the last 10 years; (2) apply advances in ultra-high-field MRI to quantify the LC in living PSP patients, together with a battery of behavioural tests of impulsivity and neuropsychology; (3) use formal models of behavior to track decision variables behind impulsive actions, and relate these to neural and disease markers, including brain network connectivity, and (4) test a repurposed drug, atomoxetine, to restore core neurocognitive systems governing the inhibition of motor responses in PSP.
Our work will promote bidirectional translational research, between non-clinical and clinical neuroscience, mapping disease states to preclinical models of cognition and behavior; and guide subsequent clinical trials with better outcome measures and patient selection and stratification.
Planned Impact
The beneficiaries of our research will extend beyond the academic environment and will include:
1. Patients with PSP: Impulsivity in PSP represents a significant burden to the affected individuals. PSP patients with problems as impulsivity and cognitive inflexibility have an increased risk of falls, injuries, chocking episodes, aspiration pneumonia, and early death. It is hoped that increasing our understanding into the brain mechanisms of impulsivity in PSP will reduce these risks. The absence of biomarkers for detecting impulsivity in PSP and the high inter-patients variability in drug response have also made the treatment of behavioural problems in PSP and other neurodegenerative disorders a major challenge. The cause of this variability in treatment response remains largely unclear, although heterogeneity in core neurochemical systems that determines a reduced sensitivity to specific therapy may play a significant role. Brain-based mechanistic accounts of impulsivity in PSP could therefore help clinical decision making and improve the management of these disabling behavioural symptoms in PSP and related disorders.
1. Non-academic clinicians: Our findings may provide useful information for clinical neurologists and other professionals who work with PSP patients (e.g., speech and language therapists, physiotherapists, and specialist nurses) and will raise awareness on a common and too often under-recognized problem in PSP. In particular, our project will reveal: (1) why some patients with PSP display impulsive behaviours and behavioral problems; (2) what happens to the brain of PSP patients with impulsive behaviours, and (3) that there are potential targets for treating impulsivity in PSP (i.e., via enhancing the noradrenergic system).
2. Carers of patients with PSP: Parents, relatives, friends, social workers, and other carers of people with PSP may also benefit from our research. In the short term our project may have a positive effect by, for example, helping carers understand PSP and its associated problems better. In the longer term, it is hoped that our results will translate into clinical trials that will provide better treatments for managing challenging behavioural syndromes in PSP.
3. Other neurodegenerative disorders: PSP is a complex disorder that share some molecular, pathophysiological, and clinical features with other neurological disorders such as Parkinson's disease, Huntington's disease, and frontotemporal dementia. Taken together, these neurodegenerative disorders represent a very significant burden to society. We therefore hope that research enabling the development of more effective interventions to manage behavioral syndromes in PSP could be also applicable to other common neurodegenerative disorders.
1. Patients with PSP: Impulsivity in PSP represents a significant burden to the affected individuals. PSP patients with problems as impulsivity and cognitive inflexibility have an increased risk of falls, injuries, chocking episodes, aspiration pneumonia, and early death. It is hoped that increasing our understanding into the brain mechanisms of impulsivity in PSP will reduce these risks. The absence of biomarkers for detecting impulsivity in PSP and the high inter-patients variability in drug response have also made the treatment of behavioural problems in PSP and other neurodegenerative disorders a major challenge. The cause of this variability in treatment response remains largely unclear, although heterogeneity in core neurochemical systems that determines a reduced sensitivity to specific therapy may play a significant role. Brain-based mechanistic accounts of impulsivity in PSP could therefore help clinical decision making and improve the management of these disabling behavioural symptoms in PSP and related disorders.
1. Non-academic clinicians: Our findings may provide useful information for clinical neurologists and other professionals who work with PSP patients (e.g., speech and language therapists, physiotherapists, and specialist nurses) and will raise awareness on a common and too often under-recognized problem in PSP. In particular, our project will reveal: (1) why some patients with PSP display impulsive behaviours and behavioral problems; (2) what happens to the brain of PSP patients with impulsive behaviours, and (3) that there are potential targets for treating impulsivity in PSP (i.e., via enhancing the noradrenergic system).
2. Carers of patients with PSP: Parents, relatives, friends, social workers, and other carers of people with PSP may also benefit from our research. In the short term our project may have a positive effect by, for example, helping carers understand PSP and its associated problems better. In the longer term, it is hoped that our results will translate into clinical trials that will provide better treatments for managing challenging behavioural syndromes in PSP.
3. Other neurodegenerative disorders: PSP is a complex disorder that share some molecular, pathophysiological, and clinical features with other neurological disorders such as Parkinson's disease, Huntington's disease, and frontotemporal dementia. Taken together, these neurodegenerative disorders represent a very significant burden to society. We therefore hope that research enabling the development of more effective interventions to manage behavioral syndromes in PSP could be also applicable to other common neurodegenerative disorders.
Organisations
- University of Cambridge (Lead Research Organisation)
- University College London (Collaboration)
- International Parkinson and Movement Disorder Society (MDS) (Collaboration)
- Van Andel Institute (Collaboration)
- The Otto-von-Guericke University Magdeburg (Collaboration)
- Ludwig Maximilian University of Munich (LMU Munich) (Collaboration)
- National Institute for Health Research (Collaboration)
- UNIVERSITY OF YORK (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- Cambridge University Hospitals NHS Foundation Trust (Project Partner)
Publications
Adams NE
(2023)
Neurophysiological consequences of synapse loss in progressive supranuclear palsy.
in Brain : a journal of neurology
Azevedo T
(2020)
A deep spatiotemporal graph learning architecture for brain connectivity analysis.
in Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference
Azevedo T
(2022)
A deep graph neural network architecture for modelling spatio-temporal dynamics in resting-state functional MRI data.
in Medical image analysis
Betts MJ
(2019)
Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases.
in Brain : a journal of neurology
Bevan-Jones RW
(2018)
[18F]AV-1451 binding is increased in frontotemporal dementia due to C9orf72 expansion.
in Annals of clinical and translational neurology
Bevan-Jones WR
(2019)
In vivo evidence for pre-symptomatic neuroinflammation in a MAPT mutation carrier.
in Annals of clinical and translational neurology
Bevan-Jones WR
(2020)
Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum.
in Brain : a journal of neurology
Bevan-Jones WR
(2018)
[18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia.
in Journal of neurology, neurosurgery, and psychiatry
Brown F
(2019)
Falls in Progressive Supranuclear Palsy
in Movement Disorders Clinical Practice
Conti A
(2019)
Variability and Reproducibility of Directed and Undirected Functional MRI Connectomes in the Human Brain
in Entropy
Cupaioli FA
(2021)
The neurobiology of human aggressive behavior: Neuroimaging, genetic, and neurochemical aspects.
in Progress in neuro-psychopharmacology & biological psychiatry
Davenport F
(2023)
Neurodegenerative disease of the brain: a survey of interdisciplinary approaches.
in Journal of the Royal Society, Interface
Di Ciò F
(2020)
Reorganization of the structural connectome in primary open angle Glaucoma.
in NeuroImage. Clinical
Dimitri G
(2022)
Multimodal and multicontrast image fusion via deep generative models
in Information Fusion
Dimitri G
(2021)
Multimodal image fusion via deep generative models
Dimitri GM
(2020)
Unsupervised stratification in neuroimaging through deep latent embeddings.
in Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference
Duggento A
(2018)
Multivariate Granger causality unveils directed parietal to prefrontal cortex connectivity during task-free MRI.
in Scientific reports
Duggento A
(2019)
A Parsimonious Granger Causality Formulation for Capturing Arbitrarily Long Multivariate Associations.
in Entropy (Basel, Switzerland)
Ewbank MP
(2018)
Psychopathic traits influence amygdala-anterior cingulate cortex connectivity during facial emotion processing.
in Social cognitive and affective neuroscience
Fairchild G
(2021)
Neuroanatomical markers of familial risk in adolescents with conduct disorder and their unaffected relatives
in Psychological Medicine
Filip AC
(2020)
A novel Graph Attention Network Architecture for modeling multimodal brain connectivity.
in Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference
Henderson SK
(2023)
Verbal fluency tests assess global cognitive status but have limited diagnostic differentiation: evidence from a large-scale examination of six neurodegenerative diseases.
in Brain communications
Hezemans FH
(2022)
Noradrenergic deficits contribute to apathy in Parkinson's disease through the precision of expected outcomes.
in PLoS computational biology
Indovina I
(2019)
Lower Functional Connectivity in Vestibular-Limbic Networks in Individuals With Subclinical Agoraphobia.
in Frontiers in neurology
Indovina I
(2020)
Structural connectome and connectivity lateralization of the multimodal vestibular cortical network.
in NeuroImage
Kaalund SS
(2020)
Locus coeruleus pathology in progressive supranuclear palsy, and its relation to disease severity.
in Acta neuropathologica communications
Lansdall CJ
(2018)
White matter change with apathy and impulsivity in frontotemporal lobar degeneration syndromes.
in Neurology
Low A
(2020)
In vivo neuroinflammation and cerebral small vessel disease in mild cognitive impairment and Alzheimer's disease.
in Journal of neurology, neurosurgery, and psychiatry
Mak E
(2021)
Imaging tau burden in dementia with Lewy bodies using [18F]-AV1451 positron emission tomography
in Neurobiology of Aging
Malpetti M
(2020)
Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy.
in Annals of neurology
Malpetti M
(2020)
The prognostic role of microglia and tau PET in Alzheimer's disease The role of microglia activation in the development of amyloid and tau pathology in Alzheimer's disease
in Alzheimer's & Dementia
Malpetti M
(2021)
In vivo PET imaging of neuroinflammation in familial frontotemporal dementia.
in Journal of neurology, neurosurgery, and psychiatry
Malpetti M
(2023)
Microglial activation in the frontal cortex predicts cognitive decline in frontotemporal dementia.
in Brain : a journal of neurology
Malpetti M
(2021)
Neuroinflammation predicts disease progression in progressive supranuclear palsy.
in Journal of neurology, neurosurgery, and psychiatry
Malpetti M
(2020)
Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.
in Brain : a journal of neurology
Malpetti M
(2022)
In Vivo 18F-Flortaucipir PET Does Not Accurately Support the Staging of Progressive Supranuclear Palsy.
in Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Malpetti M
(2023)
Synaptic Loss in Frontotemporal Dementia Revealed by [11 C]UCB-J Positron Emission Tomography.
in Annals of neurology
Nicastro N
(2020)
Gray matter changes related to microglial activation in Alzheimer's disease.
in Neurobiology of aging
Nicastro N
(2020)
Correlation of microglial activation with white matter changes in dementia with Lewy bodies.
in NeuroImage. Clinical
Nigro S
(2019)
Reduced cortical folding in multi-modal vestibular regions in persistent postural perceptual dizziness.
in Brain imaging and behavior
Nucci C
(2020)
Diffusional Kurtosis Imaging of White Matter Degeneration in Glaucoma.
in Journal of clinical medicine
| Title | Painting by Alan Rogerson |
| Description | Alan Rogerson attended the talk by Dr Luca Passamonti in 2018, where Luca discussed PSP and the methods of PET to study this disease. Alan draw an artistic inspiration from Luca's talk and in result produced the painting. |
| Type Of Art | Artwork |
| Year Produced | 2018 |
| Impact | As above. |
| Title | Pint of Science |
| Description | Pint of Science festival presentations in pubs, bringing research progress and ideas to the public. |
| Type Of Art | Performance (Music, Dance, Drama, etc) |
| Year Produced | 2018 |
| Impact | Wide public interest -sell out events |
| Description | Cambridge Dementia Course |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| URL | http://www.cambridgedementiacourse.com/index.html |
| Description | Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria (May 2017). |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| URL | https://onlinelibrary.wiley.com/doi/abs/10.1002/mds.26987 |
| Description | Guide to cognition in PSP |
| Geographic Reach | Europe |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | A guide to identifying and treating cognitive deficits in PSP and CBD, for the PSP- association, to educate and inform GPs and allied healthcare practitoners |
| Description | UHF Research Review in Parkinsonism |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in systematic reviews |
| Description | Video on PSP diagnosis -its not parkinson s- |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Education video for healthcare workers, and GPs |
| URL | https://www.youtube.com/watch?v=JlNwrq9wb2w |
| Description | (Dr Sanne Kaalund) Dating protein aggregates in degenerative tauopathies, to model disease progression |
| Amount | £4,754 (GBP) |
| Organisation | Alzheimer's Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2020 |
| End | 01/2021 |
| Description | Biomedical Research Centre Dementia Theme |
| Amount | £118,000,000 (GBP) |
| Funding ID | RG85367 |
| Organisation | National Institute for Health Research |
| Department | NIHR Biomedical Research Centre |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 03/2022 |
| Description | Brain Network Analysis in Neurodegenerative Tauopathies |
| Amount | £22,391 (GBP) |
| Funding ID | RG89925 |
| Organisation | The Evelyn Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 12/2019 |
| Description | Dating protein aggregates in neurodegenerative disease |
| Amount | 1,799,000 kr. (DKK) |
| Organisation | Lundbeck Foundation |
| Sector | Charity/Non Profit |
| Country | Denmark |
| Start | 03/2022 |
| End | 02/2024 |
| Description | Measuring microscopic changes at the macroscopic level in frontotemporal dementia - Fellowship to Sanne S. Kaalund |
| Amount | 400,000 kr. (DKK) |
| Funding ID | R232-2016-2333 |
| Organisation | Lundbeck Foundation |
| Sector | Charity/Non Profit |
| Country | Denmark |
| Start | 08/2017 |
| End | 07/2019 |
| Description | Restoring noradrenergic function to improve apathy in Parkinson s disease to Claire O Callaghan |
| Amount | £49,677 (GBP) |
| Funding ID | RG90797 |
| Organisation | Parkinson's UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2017 |
| End | 07/2018 |
| Title | LC atlas |
| Description | An atlas of locus ceruleus, currently as submisison in BioRxiv and and awaiting reviewers approval in Neuroimagine. This work is led by Dr Rong Ye. |
| Type Of Material | Physiological assessment or outcome measure |
| Year Produced | 2020 |
| Provided To Others? | Yes |
| Impact | Early and profound pathological changes are evident in the locus coeruleus (LC) in dementia and Parkinson's disease, with effects on arousal, attention, cognitive and motor control. The LC can be identified in vivo using non-invasive magnetic resonance imaging techniques which have potential as biomarkers for detecting and monitoring disease progression. We created a probabilistic atlas of the LC from 53 healthy older volunteers (52-84 years) using a sensitive magnetisation transfer sequence and ultrahigh field 7T MRI to investigate the LC structure in vivo at high-resolution. We would like to make the atlas available on NITRC for researchers, for replication or to facilitate accurate LC localisation and unbiased contrast extraction in future cognitive and clinical studies. |
| Description | Cambridge Centre for Parkinson-Plus (CCPP) |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Clinical Research Programme 1 - Biomarker investigation Clinical Trial 1: Atomoxetine in PSP patients |
| Collaborator Contribution | several |
| Impact | publications pending |
| Start Year | 2018 |
| Description | Cambridge LMU strategic partnership |
| Organisation | Ludwig Maximilian University of Munich (LMU Munich) |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | A new strategic partnership to build a common research framework on cognitive reserve, resilience and dementia Bilateral meetings, joint grant writing, and visiting professorships |
| Collaborator Contribution | A new strategic partnership to build a common research framework on cognitive reserve, resilience and dementia Bilateral meetings, joint grant writing, and visiting professorships |
| Impact | Internal reports and new grant proposals |
| Start Year | 2019 |
| Description | Claire O Callaghan - Restoring noradrenergic function to improve apathy in Parkinson s disease |
| Organisation | University of Cambridge |
| Department | Department of Psychiatry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Input on study design |
| Collaborator Contribution | Study design, will do data collection and analyses, publications pending |
| Impact | publications still pending |
| Start Year | 2017 |
| Description | Dating protein aggregates in degenerative tauopathies, to model disease progression |
| Organisation | University of York |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Intellectual idea was conveyed by Dr Sanne Kaalund. The collaboration is at the stage of Dr Kaalund sending over the extracted tau fibrils. |
| Collaborator Contribution | Prof Kirsty Penkman from York will analyse the samples to obtain racemization ratios of aminoacids. |
| Impact | Yet to be determined. |
| Start Year | 2020 |
| Description | Future collaboration discussion with Dorothy Hammerer (UCL) on atomoxetine studies within Alzheimeri's Disease |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | As above. Attendees from University of Cambridge: Prof Rowe, Dr Rong Ye, Dr Luca Passamonti, Dr Cat Rua and from UCL Dr Dorothy Hammerer. |
| Collaborator Contribution | To be discerned. |
| Impact | To be discerned. |
| Start Year | 2020 |
| Description | Genetics of neurodegeneration collaboration with Van Andel University |
| Organisation | Van Andel Institute |
| Country | United States |
| Sector | Private |
| PI Contribution | several hundred dementia case samples from longitudinal series of deep phenotyping |
| Collaborator Contribution | genotyping and genotype interpetation |
| Impact | pending |
| Start Year | 2019 |
| Description | LC collaboration |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have engaged with two UCL groups who have a shared interest in noradrenergic systems, and imaging f the locus ceruleus in particular, with data sharing and plans for joint papers. |
| Collaborator Contribution | New sequences and clinical applications of the MR technology |
| Impact | A joint position paper Data sharing |
| Start Year | 2018 |
| Description | Movement Disorder Society PSP study group |
| Organisation | International Parkinson and Movement Disorder Society (MDS) |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | 22 international sites are drawn together under this consortium, to advance PSP and CBS research and care, including biomarkers and clinical trials |
| Collaborator Contribution | Expertise, trials design, new data sharing agreement |
| Impact | Satellite meetings annually Pathology samples sharing Imaging data sharing Joint response to FDA on trial design issues |
| Start Year | 2018 |
| Description | NIHR BRC |
| Organisation | National Institute for Health Research |
| Department | NIHR Cambridge Biomedical Research Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Biomarker development, including cognitive and imaging based deep phenotyping; |
| Collaborator Contribution | Cellular, physiological, radio-chemistry, genetic and pharmaceutical innovations within a pipeline for novel drug discovery; |
| Impact | Adams, N. E., Hughes, L. E., Phillips, H. N., Shaw, A. D., Murley, A. G., Nesbit, D., Cope, T. E., Bevan-Jones, W. R., Passamonti, L., Rowe, J. B. (2020). GABA-ergic dynamics in human frontotemporal networks confirmed by pharmaco magnetoencephalography, Journal of Neuroscience, https://doi.org/10.1523/JNEUROSCI.1689-19.2019. Lewis-Smith, D. J., Wolpe, N., Ghosh, B. C. P., Rowe, J. B. (2020). Alien limb in the corticobasal syndrome: phenomenological characteristics and relationship to apraxia, Journal of Neurology, https://doi.org/10.1007/s00415-019-09672-8. Jabbari, E., Chelban, V., Holland, N., Jones, P. S., Lamb, R., Rawlinson, C., Guo, T., Costantini, A. A., Tan, M. M. X., Heslegrave, A. J., Roncaroli, F., Klein, j. C., Ansorge, O., Allinson, K. S. J., Jaunmuktane, Z., Holton, J. L., Revesz, T., Warner, T. T., Lees, A. J., Zetterberg, H., Russell, L. L., Bocchetta, M., Rohrer, J. D., Williams, N. M., Grosset, D. G., Burn, D. J., Pavese, N., Gerhard, A., Kobylecki, C., Leigh, P. G., Church, A., Hu, M. T. M., Woodside, J., Houlden, H., Rowe, J. B., Morris, H. R. (2020). Diagnosis across the spectrum of progressive supranuclear palsy and corticobasal syndrome, JAMA Neurology, doi:10.1001/jamaneurol.2019.4347. van der Ende, E. L,, Meeter, L. H., Poos, J. M., Panman, J. L., Jiskoot, L. C., Dopper, E. G. P., Papma, J. M., de Jong, F. J., Verberk, I., Teunissen, C. E., Rizopoulos, D., Heller, C., Convery, R. S., Moore, K. M., Bocchetta, M., Neason, M., Cash, D. M., Borroni, B., Galimberti, D., Sanchez-Valle, R., Laforce, Jr R., Moreno, F., Synofzik, M., Graff, C., Masellis, M., Tartaglia, M. C., Rowe, J. B., Vandenberghe, R., Finger, E., Tagliavini, F., de Mendonça, A., Santana, I., Butler, C., Ducharme, S., Gerhard, A., Danek, A., Levin, J., Otto, M., Frisoni, G. B., Cappa, S., Pijnenburg, Y. A. L., on behalf of the GENetic Frontotemporal Dementia Initiative (GENFI), Rohrer, J. D., van Swieten, J. C. (2019). Longitudinal serum neurofilament light chain in genetic frontotemporal dementia: a multicentre cohort study. Lancet Neurology, 18: 1103-1111, https://doi.org/10.1016/S1474-4422(19)30354-0. Shafto, M. A., Henson, R. N., Matthews, F. E., Taylor, J. R., Emery, T., Erzinclioglu, S., Hanley, C., Rowe, J. B., Cusack, R., Calder, A. J., Marslen-Wilson, W. D., Duncan, J., Dalgleish, T., Brayne, C., Cam-CAN, Tyler, L. K. (2019). Cognitive Diversity in a Healthy Aging Cohort: Cross-Domain Cognition in the Cam-CAN Project, Journal of Aging and Health, doi: 10.1177/0898264319878095 [ahead of print], PMID: 31592706 Lansdall, C. J., Coyle-Gilchrist, I. T. S., Vázquez Rodríguez, P., Wilcox, A., Wehmann, E., Robbins, T. W., Rowe, J. B. (2019). Prognostic importance of apathy in syndromes associated with Frontotemporal lobar Degeneration, Neurology, 92(14):e1547-e1557. doi: 10.1212/WNL.0000000000007249, PMID: 30842292, PMC: 6448451. Borchert, B. J., Rittman, T., Rae, C. L., Passamonti, L., Jones, P. S., Vatansever, D., Vazquez-Rodriguez, P., Ye, Z., Nombela, C., Hughes, L. E., Robbins, T. W., Rowe, J. B. (2019). Atomoxetine and citalopram alter brain network organization in Parkinson's disease, Brain Communications, 1:1 fcz013, https://doi.org/10.1093/braincomms/fcz013. PMID: [pending], PMC: [pending]. Nicastro, N., Surendranathan, A., Mak, E., Rowe, J. B.*, O'Brien, J. T.* (2019). 11C-PK11195 PET imaging and white matter changes in Parkinson's disease dementia, Annals of Clinical and Translational Neurology, doi: 10.1002/acn3.50877, PMID: 31507085, PMC: [pending]. Low, A., Mak, E., Malpetti, M., Chouliaras, L., Nicastro, N., Su, L., Holland, N., Rittman, T., Vázquez Rodríguez, P., Passamonti, L., Bevan-Jones, W. R., Jones, P. S., Rowe, J. B.*, O'Brien, J. T.* (2019). Asymmetrical atrophy of thalamic subnuclei in Alzheimer's disease and amyloid-positive mild cognitive impairment is associated with key clinical features, Alzheimer's & Dementia: Diagnosis, Assessment, & Disease Monitoring, 11: 690-699, DOI: https://doi.org/10.1016/j.dadm.2019.08.001, PMID: 31667328, PMC: 6811895. Tavares, T. P., Mitchell, D. G. V., Coleman, K., Shoesmith, C., Bartha, R., Cash, D. M., Moore, K. M., van Swieten, J. C., Borroni, B., Galimberti, D., Tartaglia, M. C., Rowe, J. B., Graff, C., Tagliavini, F., Frisoni, G., Cappa, S., Laforce, R. Jr, de Mendonça, A., Sorbi, S., Wallstrom, G., Masellis, M., Rohrer, J. D., Finger, E. C., GENetic Frontotemporal Dementia Initiative (GENFI) (2019). Ventricular volume expansion in presymptomatic genetic frontotemporal dementia, Neurology, doi: 10.1212/WNL.0000000000008386, PMID: 31578297, PMC: [pending]. Passamonti, L., Tsvetanov, K. A., Jones, P. S., Bevan-Jones, W. R., Arnold, R., Borchert, R. J., Mak, E., Su, L., O'Brien, J. T.*, Rowe, J. B.* (2019). Neuroinflammation and functional connectivity in Alzheimer's disease: interactive influences on cognitive performance, Journal of Neuroscience, doi: 10.1523/JNEUROSCI.2574-18.2019. PMID: 31320450, PMC: 6733539. Jabbari, E., Woodside, J., Guo, T., Magdalinou, N. K., Chelban, V., Athauda, D., Lees, A. J., Foltynie, T., Houlden, H., Church, A., Hu, M. T., Rowe, J. B., Zetterberg, H., Morris, H. R. (2019). Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes, Journal of Neurology, Neurosurgery and Psychiatry, 90(7):768-773. doi: 10.1136/jnnp-2018-320151. PMID: 30867224, PMC: 6585258. Hughes, L. E., Henson, R. N., Pereda, E., Bruña, R., López-Sanz, D., Quinn, A. J., Woolrich, M. W., Nobre, A. C., Rowe, J. B., Maestú, F., BioFIND Working Group (2019). Biomagnetic biomarkers for dementia: A pilot multicentre study with a recommended methodological framework for magnetoencephalography, Alzheimers & Dementia (Amsterdam, Netherlands), 11:450-462. doi: 10.1016/j.dadm.2019.04.009. PMID: 31431918, PMC: 6579903. Shaw, A. D., Hughes, L. E., Moran, R., Coyle-Gilchrist, I., Rittman, T., Rowe, J. B. (2019). In Vivo Assay of Cortical Microcircuitry in Frontotemporal Dementia: A Platform for Experimental Medicine Studies. Cerebral Cortex. 2019. doi: 10.1093/cercor/bhz024. PMID: 31216360. van Eimeren, T., Antonini, A., Berg, D., Bohnen, N., Ceravolo, R., Drzezga, A., Höglinger, G. U., Higuchi, M., Lehericy, S., Lewis, S., Monchi, O., Nestor, P., Ondrus, M., Pavese, N., Peralta, M.C., Piccini, P., Pineda-Pardo, J. Á., Rektorová, I., Rodríguez-Oroz, M., Rominger, A., Seppi, K., Stoessl, A. J., Tessitore, A., Thobois, S., Kaasinen, V., Wenning, G., Siebner, H. R., Strafella, A. P., Rowe, J. B. (2019). Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimers & Dementia (Amsterdam, Netherlands). 11:301-309. doi: 10.1016/j.dadm.2019.01.011. PMID: 30984816, PMC: 6446052. Rittman, T., Borchert, R., Jones, P. S., van Swieten, J., Borroni, B., Galimberti, D., Masellis, M., Tartaglia, M. C., Graff, C., Tagliavini, F., Frisoni, G. B., Laforce, R. Jr, Finger, E., Mendonça, A., Sorbi, S., Rohrer, J. D., Rowe, J. B., GENetic Frontotemporal Dementia Initiative (GENFI) (2019). Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia, Neurobioly of Aging, 77:169-177. doi: 10.1016/j.neurobiolaging.2018.12.009, PMID: 30831384; PMC: 6491498. Bevan-Jones, W. R., Cope, T. E., Jones, P. S., Passamonti, L., Hong, Y. T., Fryer, T., Arnold, R., Coles, J. P., Aigbirhio, F. I., O'Brien, J. T., Rowe, J. B. (2019). In vivo evidence for pre-symptomatic neuroinflammation in a MAPT mutation carrier. Annals of Clinical Translational Neurology, 6(2):373-378. doi: 10.1002/acn3.683. PMID: 30847369; PMC: 6389753. |
| Start Year | 2017 |
| Description | Supervisor with Caius Higher Aspiration Scheme - Rebecca Williams (Rowe Group) |
| Organisation | University of Cambridge |
| Department | Gonville and Caius College |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Supervisor to 6 students (Year 12) |
| Collaborator Contribution | Aspiration Scheme |
| Impact | Student development. |
| Start Year | 2022 |
| Description | Ultrahigh resolution imaging of neurodegeneration and vascular risk in aging and preclinical and prodromal Alzheimer's Disease |
| Organisation | The Otto-von-Guericke University Magdeburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | New consortium to faciliate and validate 7T in dementia research, across 15 EU sites. Meets and draft preparation |
| Collaborator Contribution | Led by Prof Duzel, Magdeburg, a consortium building on EUFIND. |
| Impact | None yet. Funding sought |
| Start Year | 2019 |
| Title | Atomoxetine in PSP |
| Description | new drug strategy for impulsivity in PSP to be tested for first time. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2017 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | reduced impulsivity in selected patients |
| Title | Biomarker evaluation of 7T MRI in dementia |
| Description | evaluation of novel 7T MRI for early detection of pathology in AD, and other dementias, building on the JPND consortium "EUFIND" |
| Type | Diagnostic Tool - Imaging |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2020 |
| Development Status | Under active development/distribution |
| Impact | stronger links to basic cognitive neurosciences of memory systems, and to multi-centre clinical transnational centres across EU |
| Description | (Dr Sanne Kaalund) 121st Meeting of the British Neuropathological Society 4-6 March 2020 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | Dr Kaalund presented the following talk: Locus coeruleus pathology in progressive supranuclear palsy is associated with disease severity. Day: Friday 6th March 2020 Time: 09:45:00 |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.bns.org.uk/event/121st-meeting-of-the-bns/ |
| Description | 121st British Neuropathological Society Annual Meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The meeting is focused on neuropathology, this year with special focus on neurodegenerative diseases and prion-like properties of mis-folded proteins in dementia. Dr Sanne Kaalund will be giving the talk titled "Locus coeruleus pathology in progressive supranuclear palsy, and its relation to disease severit." |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.bns.org.uk/event/121st-meeting-of-the-bns/ |
| Description | All About Brians - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | Virtual contribution at Storyhouse Theatre Chester, UK. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Atlas-based in vivo Measurement of Human Locus Coeruleus in Neurodegenerative Disorders with 7T MRI (OHBM 2020) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | Showcasing the application of the 7T Locus Coeruleus Atlas in neurodegenerative disorders. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.humanbrainmapping.org/i4a/pages/index.cfm?pageid=3958 |
| Description | Bevan-Jones, W. R. Current practice and future directions. PSP Association Public Meeting (2017) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | Bevan-Jones, W. R. (2017). Current practice and future directions. PSP Association Public Meeting, Crewe, UK. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Big Biology Day - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Live at Hills Road Sixth Form, collaboration with ARUK |
| Year(s) Of Engagement Activity | 2022 |
| Description | Brain Models & Pipecleaner Neurons (Rebecca Williams - Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Collaboration with CHaOS - live at school in St. Neots, UK |
| Year(s) Of Engagement Activity | 2022 |
| Description | British Neuropathological Society meeting, Cirencester, UK 3-5 July 2019 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Attended by Dr Luca Passamonti and Dr Sanne Kaalund to strenghten their network in neuropathology research. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.bns.org.uk/wp-content/uploads/2018/12/Programme_BNSSummerSchool2019.pdf |
| Description | British Neuropsychiatry Association guest lecture - Apathy and Impulsivity in FTLD - not all dopamine, degeneration and death - Oxford 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | TBC |
| Year(s) Of Engagement Activity | 2019 |
| Description | CCPP patient liaison |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | A patient liaison group, to advise and feedback on experience of research participation, and future studies' documentation. |
| Year(s) Of Engagement Activity | 2018,2019 |
| Description | CHaOS Summer Roadshow (Rebecca Williams - Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | Live at Poacher Scout's Jamboree (over 6000 in attendance) |
| Year(s) Of Engagement Activity | 2022 |
| Description | Care pathways for CBD |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Working group to develop new care pathways and national standards of care for CBD and related disorders |
| Year(s) Of Engagement Activity | 2018 |
| Description | Channel 4 - cognitive enhancement |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Interviews and experiment conducted under on camera, into cognitive enhancement |
| Year(s) Of Engagement Activity | 2018 |
| Description | Coping with Exam Stress - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Schools |
| Results and Impact | In collaboration with Study Together |
| Year(s) Of Engagement Activity | 2022 |
| Description | Dementia Chatathon - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Collaboration with Dementia Researcher, watched via Youtube, Twiter & Twitch |
| Year(s) Of Engagement Activity | 2022 |
| Description | Dementia Researcher Podcasts and Fundraising events - Dr M Malpetti |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | https://www.dementiaresearcher.nihr.ac.uk/tag/dr-maura-malpetti/ |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.dementiaresearcher.nihr.ac.uk/tag/dr-maura-malpetti/ |
| Description | Diagnosis and management of PSP |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | SW Movement disroders group, event at Royal College of Physicians |
| Year(s) Of Engagement Activity | 2018 |
| Description | Dr Frank Hezemans - Festival of Neuroscience 2021 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | Presenting recent results regarding the role of the locus coeruleus in apathy in Parkinsons disease. The purpose is to generate discussion and raise awareness of the role of this brain region and in regulating cognitive deficits associated in Parkinsons disease. |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://meetings.bna.org.uk/bna2021/ |
| Description | Dr Frank Hezemans - Neuroscience Network Symposium, Cambridge (27th Jul '19) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | Approx 100 researchers attended (viewed poster presentation) on recent results from Parkinsons disease study, focusing on mechanisms of sensory/motor integration and potential benefit of treatment by atomoxetine. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.neuroscience.cam.ac.uk/events/ABC2019/pages/about-abc.html |
| Description | Dr Frank Hezemans - Poster presentation at International Behavioral Neuroscience Society 2020 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | Approx 100 researchers attended (viewed poster presentation) on recent results from Parkinsons disease study, focusing on mechanisms of sensory/motor integration and potential benefit of treatment by atomoxetine. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.ibnsconnect.org/ibns-2020-annual-meeting |
| Description | Dr Frank Hezemans - Science Night 2021 prerecorded talk aimed at the general public about Parkinson's disease and noradrenaline |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Public event discussing various research studies bering carried out at MRC Cognition and Brain Sciences unit (University of Cambridge). Dr Hezemens focuses particularly on discussing Parkinson's disease and the effects of noradrenaline on the brain. |
| Year(s) Of Engagement Activity | 2021 |
| URL | https://www.mrc-cbu.cam.ac.uk/blog/2020/01/mrc-cbu-science-night-cambridge-science-festival-2020/ |
| Description | Dr Maura Malpetti (Rowe Group): Oral Presentation at DPUK Translation 2023 Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral presentation on "Post mortem validation of in vivo PET imaging: test case of inflammation in progressive supranuclear palsy" |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.dementiasplatform.uk/research-hub/translation-2023/early-career-researchers-workshop-and... |
| Description | Dr Rong Ye talk at Cambridge Centre for Parkinson's Plus (4th May 2020) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | Presented research results on the application of 7T sequence and Atlas in the Parkinsonian diseases. |
| Year(s) Of Engagement Activity | 2020 |
| Description | Effective Note Taking Strategies: Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Schools |
| Results and Impact | Collaboration with Study Together |
| Year(s) Of Engagement Activity | 2022 |
| Description | FTD UK Conference, Cambridge UK 2019 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | A UK wide cross sector meeting on advances in FTD, from basic science to new theapeutics |
| Year(s) Of Engagement Activity | 2019 |
| URL | http://www.ftduk.org/ |
| Description | Filmed Charity Broadcast for PSP Association |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | PSPA broadcast. |
| Year(s) Of Engagement Activity | 2022 |
| Description | How to Tackle an Academic Paper - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | How to Tackle an Academic Paper |
| Year(s) Of Engagement Activity | 2022 |
| Description | How to tackle Academic Teading and Writing - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | Summer CAMP collaboration. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Inernational symposium on PSP/CBD |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | International symposium, including talk and posters from our group, on progress in PSP and CBD reesarch Engagement with Pharma |
| Year(s) Of Engagement Activity | 2018 |
| Description | International Congress of Parkinson's Disease and Movement Disorders - Nice 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Advances in PSP and its overlap with FTD, main meeting and satellite symposia on PSP and Brain Imaging |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.mdscongress.org/Congress-Branded/19FP-_blue_puzzle_online.pdf |
| Description | Invited speakers (Dr Rong Ye and Dr Cat Rua) to present 7T Locus Coerelus at the Danish Research Centre for Magnetic Resonance (Oct 2019) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | Dr Rong Ye and Dr Cat Rua were invited to discuss the 7T research conducted at University of Cambridge. Future actions for collaborations were also discussed. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Lansdall, C. (May 2018). Organising Committee for Pint of Science, Annual Science Festival, Castle Bar, Cambridge, UK |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Discuss science with general public. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Let's Talk Science - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Skyped in to Birmingham, USA |
| Year(s) Of Engagement Activity | 2022 |
| Description | Let's Talk Science! Skype a Scientist, Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Schools |
| Results and Impact | Engagement via Skype a Scientist to Missouri, USA. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Locus Coeruleus Imaging Meeting Magdeburg 2019 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This workshop was attended by Dr Luca Passamonti, Dr Sanne Kaalund, Dr Rong Ye and Dr Catarina Rua. The team were showcasing research in LC and the use of 7T. At this years LC meeting, we aim to focus on the following questions: 1. How can we improve structural / functional / PET LC imaging? 2. What is the role and fate of the LC in neurodegenerative and clinical conditions? What renders the LC particularly vulnerable? 3. What have we learned (also from animal research) on the LCs role in cognition and behavior in the last years? 4. What are the most promising interventions targeting the LC / NA system? We will post a detailed program on the website and send it via email to all registered users at a later date. Please see information on our previous meeting held last February and the resultant consensus paper summarizing how LC imaging can be used for clinical research in neurodegenerative diseases. New for this years meeting are 1-2 methods workshops for those interested: A two day hackathon (Saturday 14th and Sunday 15th) where MR physicists will do some hands-on tests to explore new imaging approaches (this will be mostly relevant for MR physicists doing LC imaging) If there is enough interest, an extra session on LC methods in animal research (electrophysiology, high-field imaging, optogenetics, ...) which will take place on Saturday 14th. Please let us know if you would like to join either of these! |
| Year(s) Of Engagement Activity | 2019 |
| URL | http://www.iknd.ovgu.de/LC+Meeting+2019.html |
| Description | Oral Presentation - Dr K Stockton "Metabolomic effects of sporadic, genetic and pre-symptomatic frontotemporal dementia" |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Metabolomic effects of sporadic, genetic and pre-symptomatic frontotemporal dementia. GENFI winter meeting International meeting of research study |
| Year(s) Of Engagement Activity | 2022 |
| Description | Oral Presentation @ ADPD Barcelona 20222- Dr M Malpetti |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | "In vivo PET imaging of inflammation as a prognostic tool in frontotemporal dementia" - ADPD conference (Barcelona, 03/2022) |
| Year(s) Of Engagement Activity | 2022 |
| Description | Oral Presentation Dr D Street at Midlands Neurological Society Meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral presentation Non-motor markers predict survival in PSP |
| Year(s) Of Engagement Activity | 2022 |
| Description | Oral Presentation at International FRONTIER research conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | PET Imaging in PSP |
| Year(s) Of Engagement Activity | 2023 |
| Description | Oral Presentation: Caius Higher Aspiration Scheme - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Caius Higher Aspiration Scheme |
| Year(s) Of Engagement Activity | 2023 |
| Description | PPE - Cambridge university Hospitals Trust members |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | An evening event for the members of the Trust (patients, and local public) to discuss advances in dementia research and care, including the insights from new technologies |
| Year(s) Of Engagement Activity | 2019 |
| Description | PSP Matters |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Extended interview on PSP research, researchers, motivation and progress. How donations lead to real research progress, and added value |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://pspassociation.org.uk/information-and-support/just-been-diagnosed/psp-matters/ |
| Description | PSP carers meeting |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Special meeting to initiate a PSP support network locally, and engage families with PSP mattes, clinical and research, and the local team |
| Year(s) Of Engagement Activity | 2018 |
| Description | PSPA Research Day - Oral Presentation Dr K Stockton |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | "Pick's disease and Progressive supranuclear palsy Prevalence and Incidence study (PiPPIN)" 3/2/23 PSPA Research Day Research day for patients and carers, organised by the PSP association |
| Year(s) Of Engagement Activity | 2022 |
| Description | Passamonti, L. (16th May 2018). Halting nerve cell death and improving quality of life in progressive supranuclear palsy. Pint of Science, Annual Science Festival, Castle Bar, Cambridge, UK |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Discuss science with general public. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Pint of Science: Atoms to Galaxies |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Events held live in Cambridge UK |
| Year(s) Of Engagement Activity | 2022 |
| Description | Poster Presentation Association of British Neurologists - Dr K Stockton |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster presentation titled: Pick's disease and Progressive supranuclear palsy Prevalence and Incidence study (PiPPIN) |
| Year(s) Of Engagement Activity | 2022 |
| Description | Rowe - 11th Cambridge Dementia Course. Oliver Cousins for Advances in Clinical Neuroscience and Rehabilitation (ACNR), (2017). |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Rowe, J. B. (11th April 2017). 11th Cambridge Dementia Course. Oliver Cousins for Advances in Clinical Neuroscience and Rehabilitation (ACNR). |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.acnr.co.uk/2017/04/11th-cambridge-dementia-course/ |
| Description | Rowe - Cambridge Science Festival (2017) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Lecture at Cambridge Science Festival |
| Year(s) Of Engagement Activity | 2017 |
| Description | Rowe - Cambridge Science Festival 2018 - Molecules to Memory - Advances in Dementia Research, hosted by ARUK local network |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | public talk at Cambridge Science Festival |
| Year(s) Of Engagement Activity | 2018 |
| Description | Rowe - FTD Carers' Meeting, Department of Clinical Neurosciences, University of Cambridge, UK (2014) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Rowe, J. B. (24th March 2014). FTD Carers' Meeting, Department of Clinical Neurosciences, University of Cambridge, UK. |
| Year(s) Of Engagement Activity | 2014 |
| Description | Rowe - FTD Carers' Meeting. Department of Clinical Neurosciences, University of Cambridge (2017). |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Rowe, J. B. (13th September 2017). FTD Carers' Meeting. Department of Clinical Neurosciences, University of Cambridge; give feedback to carers and also get feedback from them. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Rowe - FTD-UK Annual Meeting (2017) - Debate |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | A discussion of imaging's contribution to FTD diagnosis, prognosis and stratification |
| Year(s) Of Engagement Activity | 2017 |
| Description | Rowe - Look East. The latest news, sport and weather for the East of England. BBC One. (Feature about PSP Association) (2017) |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Rowe, J. B. (16th May 2017). Look East. The latest news, sport and weather for the East of England. BBC One. (Feature about PSP Association). |
| Year(s) Of Engagement Activity | 2017 |
| Description | Rowe - PSP Matters (2017) |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Research update and progress for PSPA |
| Year(s) Of Engagement Activity | 2016,2017 |
| Description | Rowe, J. B. (28th September 2017) Understanding frontotemporal dementia: an interview with Professor James Rowe - Interview for the National Institute for Health Research (NIHR) (2017) |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Rowe, J. B. (28th September 2017) Understanding frontotemporal dementia: an interview with Professor James Rowe. Interview for the National Institute for Health Research (NIHR). https://www.nihr.ac.uk/news-and-events/features/behind-the-research/Understanding-frontotemporal-dementia.htm |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.nihr.ac.uk/news-and-events/features/behind-the-research/Understanding-frontotemporal-deme... |
| Description | Rowe/Team - Cambridge Science Festival (2017) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | A lecture on the challenge of dementia as part of the Cambridge Science Festival |
| Year(s) Of Engagement Activity | 2017 |
| Description | Rowe: FTD carers meeting (2017) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Research discussion to regional carers |
| Year(s) Of Engagement Activity | 2017 |
| Description | Seven lab members (22nd March 2018). 5k for the PSP Association to raise money to support people affected by CBD & PSP, Cambridge, UK. |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | Run for PSP and CBD to increase awareness. https://www.pspassociation.org.uk/fundraising/5kforpspa/; promoted on twitter |
| Year(s) Of Engagement Activity | 2018 |
| Description | Sutton Trust MEG Talks - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Undergraduate students |
| Results and Impact | Event held at the MRC Cognition Brain Unit |
| Year(s) Of Engagement Activity | 2022 |
| Description | Vazquez, (2017); Half Marathon to raise money and awareness for patients with Progressive Supranuclear Palsy and the PSP Association, Thessaloniki Night Half-Marathon, Greece. |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Vazquez Rodriguez, P. (14th October 2017). Half Marathon to raise money and awareness for patients with Progressive Supranuclear Palsy and the PSP Association, Thessaloniki Night Half-Marathon, Greece. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Vazquez/Rowe - Fighting PSP both in and outside the lab. PSP Association Magazine (2017) |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Vazquez Rodriguez, P. (September 2017). Fighting PSP both in and outside the lab. PSP Association Magazine; raise awareness for PSP |
| Year(s) Of Engagement Activity | 2017 |
| Description | Vázquez Rodríguez; Imaging neuroinflammation in progressive supranuclear palsy and Alzheimer's disease. Talk presented at the PSP Association Annual Study Day (2017) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Vázquez Rodríguez, P. (18th October 2017). Imaging neuroinflammation in progressive supranuclear palsy and Alzheimer's disease. Talk presented at the PSP Association Annual Study Day, Milton Keynes, UK. Was evaluated as best presentation. |
| Year(s) Of Engagement Activity | 2017 |